1

A new multi-species Protein A-ELISA assay for plague diagnosis in humans and 1

2 other mammal hosts

- 3
- Matheus Filgueira Bezerra^{1§}, Camila Cavalcanti Xavier^{1§}, Alzira Maria Paiva de 4
- Almeida^{1&} and Christian Robson de Souza Reis^{1&*} 5
- ¹Departamento de Microbiologia Instituto Aggeu Magalhães; Fiocruz-PE. Recife, PE, 6
- 7 Brazil;
- 8 [§]These authors contributed equally to this work
- [&]These authors contributed equally to this work 9

10

- **Running title:** Protein A-ELISA method for multi-species plague diagnosis 11
- 12
- 13

14

- 15 * Corresponding author: Christian R S Reis;
- Av. Professor Moraes Rego, s/n, Recife/PE 50740-465, Brazil. Tel: +55-81-21012677. 16
- Email: christian.reis@fiocruz.br 17

18

- **Paper type**: Full length article 19
- Text word count: 2819 20
- 21 Abstract text count: 200
- Number of figures: 3 22
- Number of tables: 2 23
- Number of references: 27 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

²⁵ Number of Supplemental data: 4

26 Abstract

Background. The Hemagglutination assay (HA) is widely used in plague diagnosis,
however, it has a subjective interpretation and demands high amounts of antigen and other
immunobiological supplies. Conventional IgG-ELISA is limited by the need of specific
conjugates for multiple plague hosts.

Methods. Thus, we developed an ELISA Protein A-peroxidase method to detect anti-F1 antibodies across several species, including humans. To determine the cut-off and performance rates, HA results from 288 samples (81 rabbits, 64 humans, 66 rodents and 77 dogs) were used as reference.

Results. Optimal conditions were found with 250ng/well of F1 and 1:500 serum dilution.

36 Protein A-ELISA showed high repeatability and reproducibility. The positive/negative

37 OD ratios were higher in Protein A-ELISA and there was no significant cross-reaction

38 with other pathogenic versiniae. The overall sensitivity/specificity, area under the curve

and Kappa rates for Protein A-ELISA were 93.9/98.9%; 0.993 and 0.938, respectively.

40 Similar results were observed in each species separately. There was a strong agreement

41 between Protein A and IgG assays (kappa=0.973) in independent analysis (n=487).

42 **Conclusions.** Altogether, the Protein A-ELISA showed high performance when 43 compared both to HA and IgG-ELISA, with a polyvalent single protocol that requires 44 reduced amounts of antigen and can be employed to any plague hosts.

- 45 Keywords: ELISA, protein A, plague, diagnosis.
- 46
- 47
- 48
- 49
- 50

3

51 INTRODUCTION

52 Plague is a flea-transmitted disease caused by the gram-negative bacterium *Yersinia pestis* and was responsible for at least three pandemics in the past [1]. Although 53 nowadays plague can be treated with antibiotics, there is a lack of vaccines able to provide 54 long-term immunity and this disease still threaten individuals living in remote places, 55 close to wildlife hosts but distant from specialized healthcare services [2]. Human cases 56 57 and deaths are recorded annually in several countries across Africa, Asia and the Americas [3]. Despite the declining incidence worldwide, the interest in plague is 58 constant because of its potential to establish new epidemics and application as a biological 59 60 weapon [2,4].

Although the rodents are the main plague reservoir, practically any mammal can 61 be infected by Y. pestis and may take part in the dynamics of the infection [5]. An 62 63 interesting feature of plague is that, under certain conditions, the disease is able to remain quiescent in the natural foci for decades and eventually reemerge among the wild fauna 64 and spillover to human populations [6,7,8]. Due to this unique feature, it is of utmost 65 importance to perform continuous monitoring of plague areas. In this regard, serological 66 methods are an important surveillance tool, as it identifies not only animals with the active 67 68 form of the disease, but also those previously exposed [9]. Most serological tests for plague are based on the detection of antibodies against the F1 capsular antigen, which is 69 exclusive to Y. pestis, and highly immunogenic for humans and other mammals [10,11]. 70

Given its polyvalence for sera from all taxonomic family groups, hemagglutination (HA) has been widely used for plague serological diagnosis for several decades. However, some commonly observed problems in HA, such as interpretations bias, cross-reaction with other infections, high consumption of F1 antigen and use of perishable biological supplies, led many laboratories to migrate to IgG ELISA tests [12-

4

16]. On the other hand, conventional ELISA requires a specific anti-IgG conjugate and
different optimization for each mammal species. Thus, there is a need of new diagnostic
methods that can improve the diagnosis and epidemiological surveillance of human and
animal plague across the globe [2,4,17].

Alternatively to immunoglobulin (anti-IgG) conjugates, the *Staphylococcus aureus* protein A has been proposed for diagnosis of other multi-host diseases due to its universal affinity for immunoglobulins from various species of domestic and wild mammals [18-20]. To tackle this gap, we proposed a Protein A-based indirect ELISA method, able to detect anti-F1 antibodies from humans and other plague hosts within a single protocol.

86

87 METHODS

88 F1 production

The F1 antigen was extracted from the A1122 Y. pestis strain, according to the 89 protocol described by Chu [10], in a Biosafety level 3 facility. The purified product was 90 then mixed with $2 \times$ Laemmli buffer (1:1) containing 5% β -mercaptoethanol, heated at 91 100 °C for five minutes and loaded onto a 20% polyacrylamide gel (Figure 1A). The F1 92 93 antigen was quantified using the NanoDrop One^C Microvolume UV-Vis Spectrophotometer (Thermo-Fischer, USA). 94

95

96 Human and animal samples.

Initially, 288 sera (81 control rabbits, 64 humans, 66 wild rodents and 77 domestic
dogs; total positives/negatives = 98/190) with well-characterized results for HA were
used for cut-off determination and Protein A-ELISA validation. Next, 265 additional
samples with unknown HA results nor used in cut-off determination were included to

5

evaluate the agreement between the Protein A and IgG methods in ELISA. All sera were
kindly provided by the Brazilian Plague Reference Service (SRP) and originated from the
routine surveillance of the Brazilian plague areas including human cases, several rodent
species and domestic carnivores (stray dogs) that pray on rodents [21,22].

105

106 **Rabbit immunization**

107 Sera from rabbits immunized with formol-killed Y. pestis and other pathogenic Yersinia strains (whole-cells immunization) or with the purified F1 antigen, produced as 108 previously described [23] for positive control in routine diagnosis and were kindly 109 110 provided by the SRP. From the 37 positive control sera, 14 were from rabbits exposed to the reference EV76 or A1122 Y. pestis strains in independent experiments, 18 were from 111 rabbits exposed to diverse Brazilian Y. pestis strains from the Fiocruz-CYP 112 113 (http://cyp.fiocruz.br) bacterial cultures collection and five were from rabbits exposed to the purified F1 antigen (three native F1 and two recombinant F1, expressed in E. coli) 114 [23]. Additionally, to evaluate whether the ELISA test would present cross-reaction with 115 116 other Yersiniae, five rabbits immunized with distinct isolates of Yersinia pseudotuberculosis and two with Yersinia enterocolitica were included. The other 37 117 118 negative control rabbit sera were obtained from animals from the IAM facilities that did not underwent any experimental intervention. 119

120

121 Ethics Statement

The production of immune sera for positive controls in rabbits is routinely produced following the local Animal Ethics Committees (CEUA/IAM) guidelines and supplies the laboratorial diagnosis of plague by the National Plague Reference Service (SRP–IAM). Sera from rodents, dogs and humans were obtained during the routine

6

operations of the Brazilian plague surveillance program over the years and maintained inthe serum samples collection of the Instituto Aggeu Magalhães.

128

129 Protein A-ELISA and IgG-ELISA.

The ELISA tests were adapted from previously established protocols [10,13]. 130 Briefly, 96-well plates (Techno Plastic Products, Switzerland) were incubated overnight 131 with 250 ng of F1 diluted in 100 µl of a 0,05 M, pH 9,6 carbonate-bicarbonate buffer per 132 well. Next, the plates were washed twice with 500 µl of PBS per well (PW 40 Microplate 133 Washer, Bio-Rad, USA) and blocked with 100 µl of a 10% solution of low-fat milk in 134 135 PBS for one hour. After a double wash with 500 µl of PBS-T (Tween 20, 0.05%), 100 µl of serum samples diluted (1:500) in a 10% milk/PBS-T solution were incubated in the 136 plate at room temperature for one hour and washed twice with 500 µl of PBS-T. A 100 137 138 µl of Protein A-Peroxidase from Staphylococcus aureus/horseradish (Sigma-Aldrich, USA) or goat anti-human, rabbit or dog-peroxidase (Kirkegaard & Perry Laboratories, 139 140 USA) diluted in 10% milk/PBS-T solution (1:10.000 and 1:2.500, respectively) were 141 added and incubated at room temperature for one hour and washed twice with 500 µl of PBS-T. Finally, 150 µl of 2 mg/mL OPD (o-phenylenediamine dihydrochloride; Sigma-142 Aldrich) and $1:10^3$ H₂O₂ diluted in citrate-phosphate buffer (pH=5.0) was incubated in 143 each well for 30 minutes at room temperature in a dark environment. The reaction was 144 stopped by the addition of 100 μ l 2.5 M sulfuric acid (H₂SO₄) per well and plates were 145 read at the optical density of 490nm (iMark[™] Microplate Absorbance Reader, Bio-Rad, 146 USA). 147

All samples were measured in triplicates and the background (blank) optical density (OD) from each plate was subtracted from the average sample OD. Distinct concentrations of F1 antigen, peroxidase conjugates and sera dilution were tested to

7

determine optimal conditions. The cut-offs were determined according to the best specificity/sensitivity (Youden's index) from the ROC curve. A distinct cut-off was calculated for each peroxidase conjugate. Since the rodent samples included rather heterogeneous range of wild species [21], we could not test them for IgG-ELISA.

155

156 Hemagglutination assay (HA)

157 The hemagglutination (HA) assay was performed as described previously [10]. In 158 short, the F1 antigen was immobilized onto sheep red blood cells (SRBC) previously 159 fixed with glutaraldehyde and tannic acid. Next, the F1-coated SRBC (25 μ L/well) were 160 incubated with the test serum serially diluted in eight wells starting from 1/4 in HA 161 (0.85% saline + normal rabbit serum) buffer. The specificity of HA was accessed by the 162 hemagglutination inhibition (HI). The test is considered positive when the HA endpoint 163 is depressed by three or more HI dilutions (titers > 1/16 are considered positive).

164

165 Statistical Analysis

The HA test, which is routinely used in the SRP, was used as the gold standard to 166 calculate Protein-A ELISA and IgG ELISA performance rates. Sensitivity, specificity, 167 168 accuracy and confidence intervals were calculated using the https://www.medcalc.org platform. Receiver Operating Characteristic (ROC) curves, area under the curve (AUC), 169 scatterplots and correlations were calculated with the GraphPad Prism version 5 software. 170 Pearson test was used to measure the correlation between ODs from distinct tests and 171 Mann-Whitney test was used to compare OD means. The intra and inter-assay variability 172 173 was measured using the coefficient of variation (CV) from one serum from a rabbit immunized with the A1122 Y. pestis strain and one negative rabbit serum. Samples were 174 tested in eight replicates within runs and across six experiments in non-consecutive days. 175

8

The Kappa test was initially applied to determine the agreement rate between the 176 177 ELISA and HA tests (n=288) and then, between Protein A-ELISA and IgG-ELISA calculated using 178 (n=487). The index was the Quickcalc Graphpad tool (https://www.graphpad.com/quickcalcs/kappa2). Statistical tests were applied with a 179 95% confidence interval. 180 181 182

- 183
- 184 **RESULTS**

185 Standardization of Protein A-ELISA and IgG-ELISA

The optimal conditions were determined for Protein A-ELISA by evaluating 186 separately distinct amount of F1 antigen per well and serum dilutions. There was no 187 188 significant difference between the ODs by using the amounts of 250, 375 and 500 ng per well (Figure 1B). Thus, we decided to establish the lowest amount (250 ng per well) for 189 190 the subsequent experiments. By testing three serum dilutions (1: 250; 1: 500 and 1: 1000), 191 the 1:500 dilution showed high ODs for positive samples and low background for negative samples (Figure 1C). For optimization of the three IgG-ELISA tests, we 192 maintained the amount of F1 antigen (250 ng/well) and sera dilution (1:500) previously 193 established for Protein A-ELISA and tested four dilutions for IgG conjugate (1:1250; 194 1:2500; 1:5000 and 1:10000). We found the best positive/negative ratios at the 1:2.500 195 dilutions for all IgG conjugates (Supplementary Figure 1). 196

197

198 Comparing ODs, cut-offs and cross-reaction between Protein A and IgG ELISAs

199Whilst a single cut-off was established for Protein A-ELISA considering the best

200 Youden's index possible across all tested species, individual cut-offs were established for

9

IgG anti-rabbit, anti-human and anti-dog ELISAs (Table 1 and Figure 3 A-B). We observed low background signals in negative samples for Protein A, anti-rabbit and antihuman IgG conjugates, but a rather marked background in anti-dog IgG conjugate, resulting in a narrower window of opportunity for cut-off.

Overall, the average ODs from positive samples were significantly higher than the ODs from negative samples both in protein A and in IgG tests (Mann-Whitney test $p < 10^{-3}$). The ratios between the OD means from positive and negative samples were considerably higher for the protein A conjugate (all samples = 28.7; rabbit = 81.1; human = 34.2; rodent = 51.7 and dog = 12.8), when compared to anti-rabbit (22.4), anti-human (11.8) and anti-dog (4.9) IgG conjugates. OD ratios and averages are shown in Table 1 and Supplementary Table 1, respectively.

212 We observed a good degree of correlation between ODs from Protein A and IgG-213 ELISA methods (Figure 2A). The mean ODs across six assay runs in different days were 1,392 ($\pm 0,069$) for the positive rabbit serum (A1122) and 0,046 ($\pm 0,005$) for the negative 214 215 control, with a coefficient of variation (CV) of 4.9% and 10.8%, respectively. The 216 repeatability, determined by eight intra-assay replicates, showed a CV of 0.5% for the positive anti-Y. pestis A1122 serum and 4.6% for the negative serum. Moreover, the intra-217 218 assay analysis of the triplicates from all samples tested for Protein A-ELISA revealed that 93% of the samples had a CV lower than 15% (Figure 2B). Of interest, only 2% of the 219 samples had an CV above 30% and those were negative samples with ODs close to the 220 lower detection limit, where small numeric variations imply in high CVs (Supplementary 221 Figure 2). 222

To evaluate whether these ELISA methods would present cross-reaction with other pathogenic yersiniae, sera from seven rabbits previously immunized with *Y*. *pseudotuberculosis* (five) or *Y. enterocolitica* (two) strains were tested. Although the

10

average ODs from these sera were slightly higher than other negative samples (protein A:
0.076 *versus* 0.014 and IgG: 0.133 *versus* 0.031), only one from the seven tested samples
(*Y. enterocolitica*) presented a false-positive result for Protein A-ELISA (Figure 3 A-B).

225

230 Performance of Protein A-ELISA and IgG-ELISA

231 Taking into consideration the HA results for 98 positive and 190 negative 232 reference samples, the analysis of protein A and IgG ELISAs performance rates revealed high sensitivity, specificity and accuracy rates for both methods (Table 1). The Protein 233 A-ELISA test had two false-positives (one rabbit and one dog) and six false negatives 234 235 (four rodents, one rabbit and one dog), with an overall sensitivity of 93.9% and specificity of 98.9%. On the other hand, the IgG-ELISA test had six false-positives (three humans, 236 237 two dogs and one rabbit), with a sensitivity of 97.4% and specificity of 100% for rabbits, 238 93% and 100% for humans and finally, 90% and 100% for dogs. Confirming these findings, the ROC curves from both protein A and IgG methods showed high area under 239 240 the curve (AUC) rates. Whereas the overall and species-specific AUCs from protein A-241 ELISA tests remained above 0.990, AUCs from IgG-ELISA ranged from 0.930 to 0.982 242 (Figure 3 C-D, Supplementary Figure 3).

243 The Kappa test was initially applied to measure the degree of reliability between the ELISA tests and the HA (n=288 for protein A and n=222 for IgG). Excellent 244 agreement rates were observed in samples from all species (Table 1). Next, we included 245 new 265 independent samples with unknown HA results (and not used in cut-offs 246 calculation) and calculated the kappa index to measure the agreement between Protein A 247 248 and IgG ELISAs (Table 2). From the 487 samples, 84 were positive in both tests, 398 were negative in both tests, eight were positive for protein A but negative for IgG and 249 five were positive for IgG but negative for protein A. Kappa coefficient for all species 250

11

was 0.905 (0.854-0.956), for rabbits: 0.925 (0.842-1.000), for humans: 0.914 (0.8181.000) and for dogs: 0.850 (0.741-0.959). The p-values were < 0.05 in all tests.

253

254 DISCUSSION

The gold standard for plague diagnosis is the identification and isolation of the Y. 255 pestis in bacteriological cultures from the clinical specimen. However, as proper 256 257 diagnosis is often not feasible due to the acute progression of the disease and geographic isolation of cases, patients frequently receive treatment without laboratory results [2-4]. 258 Therefore, serological testing is of most importance for plague diagnosis and surveillance 259 260 activities, as it can detect not only active infections in humans and other hosts, but also retrospectively identify individuals exposed to the bacteria [9,10]. In this scenario, 261 262 serological surveillance must consider a wide variety of mammals to be tested, such as 263 rodents and other small mammals, domestic (dogs and cats) and wild carnivores that pray on rodents [5,12,21,22,24]. 264

265 Here, we describe a Protein A-based approach designed to overcome some 266 limitations faced by routine laboratories when using other serological methods, such as HA (subjective interpretation, high consumption of antigen, perishable reagents) and 267 conventional ELISA (requires specific IgG-peroxidase conjugate, cut-off calculation and 268 positive controls for each species). While the protocol here established requires 750 ng 269 of F1 antigen per tested sample (using triplicates), HA spends 20,000 ng of F1 per tested 270 sample (considering the standard eight dilutions according to Chu [10], resulting in the 271 use of approximately twenty-seven times more antigen per sample. This difference can 272 be particularly relevant for plague diagnosis given the complexity and costs of producing 273 274 and purifying F1 from extensive Y. pestis culturing in biosafety level 3 (BSL3) laboratories [23]. 275

12

Throughout a broad range of host species hereby tested, the Protein A-ELISA 276 277 method showed high sensitivity, specificity and reproducibility rates even with a single cut-off value for all species. Corroborating these findings, the analysis of the ROC curve 278 showed AUCs above 0.990 in all groups tested in protein A-ELISA, while AUCs from 279 IgG-ELISA ranged from 0.930 to 0.982. The Cohen's Kappa test revealed high agreement 280 rates for this protocol when compared to HA (n=288) and IgG-ELISA (n=487). Since 281 282 human cases of plague have not been reported in Brazil since 2005, we were not able to estimate positive/negative predictive values [25]. 283

Remarkably, we observed a good correlation between ODs from Protein A and 284 285 anti-IgG, with higher positive/negative OD ratios in the Protein A-ELISA test, which allows a safer window of opportunity for cut-off determination between positive and 286 negative samples. Of note, little cross-reaction was observed in sera from rabbits 287 288 immunized with other pathogenic versiniae. Interestingly, whilst negative samples showed low background signals in Protein A, anti-rabbit and anti-humans IgG conjugates, 289 290 a rather marked background in anti-dog IgG conjugate was observed. This could be 291 associated to the non-specific agglutination routinely observed in sera from dogs in diagnosis by HA. 292

293 Although remaining detectable in humans for several years after infection, antibodies against Y. pestis can only be detected from the fifth day of infection by HA 294 and from the eighth day by IgG-ELISA [15,26,27]. Previous studies demonstrate that in 295 addition to its universal affinity for immunoglobulins (IgG) from almost all mammals, 296 protein A can also bind to IgA and IgM and possibly, detect infections in earlier stages of 297 infections, before serum conversion to IgG [19]. However, this hypothesis is vet to be 298 299 tested in the context of serodiagnosis of plague.

300	Altogether, we validated a new indirect ELISA test that is sensitive, specific and
301	reproducible, with a single protocol that can be used for both diagnosis of plague in
302	humans and epidemiological surveillance in animal reservoirs from active foci.
303	
304	ACKNOWLEDGMENTS
305	We are thankful to the Brazilian National Plague Reference Service staff for providing
306	the serum samples to this study.
307	
308	
309	FUNDING
310	This work was supported by the Conselho Nacional de Desenvolvimento
311	Científico e Tecnológico (CNPq; grant #422612/2016-2).
312	
313	DISCLOSURE OF CONFLICTS OF INTEREST
314	The authors have no competing financial interests to declare.
315	
316	REFERENCES
317	1. Bramanti B, Stenseth NC, Walløe L, Lei X. Plague: A disease which changed the
318	path of human civilization. Yersinia pestis: retrospective and perspective Springer
319	2016; 918:1-26.
320	2. Vallès X, Stenseth NC, Demeure C, et al. Human plague: An old scourge that
321	needs new answers. PLoS Negl Trop Dis 2020; 14:e0008251.
322	3. WHO - World Health Organization. Plague around the world in 2019. Weekly
323	Epidemiological Record. Available at
324	https://www.who.int/wer/2019/wer9425/en/. Accessed 25 February 2021.

325	4.	Stenseth NC, Atshabar BB, Begon M, et al. Plague: past, present and future. PLoS
326		Medicine 2008; 5:9-13.
327	5.	Mahmoudi A, Krytufek B, Sludsky A, et al. Plague reservoir species throughout
328		the world. Int Zool 2020; 0:1-14.
329	6.	Gage KL. Factors Affecting the Spread and Maintenance of Plague. Advances in
330		Yersinia Research Springer 2012; 954:79-94.
331	7.	Jones SD, Atshabar B, Schmid BV, Zuk M, Amramina A, Stenseth NC. Living
332		with plague: Lessons from the Soviet Union's antiplague system. PNAS 2019;
333		116:9155-163.
334	8.	Mead PS. Plague in Madagascar - A Tragic Opportunity for Improving Public.
335		Health. N Engl J Med 2018; 378:106-8.
336		
337	9.	Denis DT, Gage KL, Gratz N, Poland JD, Tikhomirov E. Plague manual:
338		Epidemiology, Distribution, Surveillance and Control. WHO 1999. Available at:
339		https://www.who.int/csr/resources/publications/plague/whocdscsredc992a.pdf?u
340		<u>a=1</u> . Accessed 25 February 2021.
341	10	Chu M. Laboratory Manual of Plague Diagnostic Tests. Centers for Disease
342		Control and Prevention. World Health Organization 2000.
343	11.	Demeure CE, Dussurget O, Guillem MF, Le Guern AS, Savin C, Pizarro-Cerdá J.
343 344	11.	. Demeure CE, Dussurget O, Guillem MF, Le Guern AS, Savin C, Pizarro-Cerdá J. <i>Yersinia pestis</i> and plague: an updated view on evolution, virulence determinants,
343 344 345	11.	Demeure CE, Dussurget O, Guillem MF, Le Guern AS, Savin C, Pizarro-Cerdá J. <i>Yersinia pestis</i> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. Gen Imm 2019; 20:357-70.
343 344 345 346	11.	 Demeure CE, Dussurget O, Guillem MF, Le Guern AS, Savin C, Pizarro-Cerdá J. <i>Yersinia pestis</i> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. Gen Imm 2019; 20:357-70. Esamaeili S, Azadmanesh K, Naddaf SR, Rajerison M, Carniel E, Mostafavi E.
343 344 345 346 347	11.	 Demeure CE, Dussurget O, Guillem MF, Le Guern AS, Savin C, Pizarro-Cerdá J. <i>Yersinia pestis</i> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. Gen Imm 2019; 20:357-70. Esamaeili S, Azadmanesh K, Naddaf SR, Rajerison M, Carniel E, Mostafavi E. Serologic survey of plague in animals, Western Iran. Emerg Infect Dis 2013;
343 344 345 346 347 348	11.	 Demeure CE, Dussurget O, Guillem MF, Le Guern AS, Savin C, Pizarro-Cerdá J. <i>Yersinia pestis</i> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. Gen Imm 2019; 20:357-70. Esamaeili S, Azadmanesh K, Naddaf SR, Rajerison M, Carniel E, Mostafavi E. Serologic survey of plague in animals, Western Iran. Emerg Infect Dis 2013; 19:1549-51.

349	13. Almeida AMP, Ferreira LCS. Evaluation of three serological tests for the
350	detection of human plague in northeast Brazil. Mem Inst Oswaldo Cruz 1992;
351	87:87-92

- 14. Rajerison M, Dartevelle S, Ralafiarisoa LA, et al. Development and Evaluation of
 Two Simple, Rapid Immunochromatographic Tests for the Detection of *Yersinia pestis* Antibodies in Humans and Reservoirs. PLoS Negl Trop Dis 2009; 3:e421.
- 15. Rasoamanana B, Leroy F, Boisier P, Rasolomaharo M, Buchy F, Carniel E,
 Chanteau S. Field evaluation of an immunoglobulin G anti-F1 enzyme-linked
 immunosorbent assay for serodiagnosis of human plague in Madagascar. Clin
 Diagn Lab Immunol 1997; 4:587-91.
- 359 16. Shepherd AJ, Leman PA, Hummitzsch DE, Swanepoel R. A comparison of
 360 serological techniques for plague surveillance. Trans R Soc Trop Med Hyg 1984;
 361 78:771-73.
- 362 17. Baril L, Vallès X, Stenseth NC, et al. Can we make human plague history? A call
 363 to action. BMJ Global Health 2019; 4:e001984.
- 364 18. Goudswaard J, Vander Donk JA, Noordzij A, Van Dam RH, Vaerman JP. Protein
 365 A reactivity of various mammalian immunoglobulins. Scand J Immunol 1978;
 366 8:21-8.
- 367 19. Kelly PJ, Tagwira M, Matthewman L, Mason PR, Wright EP. Reactions of sera
 368 from laboratory, domestic and wild animals in Africa with protein A and a
 369 recombinant chimeric protein AG. Comp Immunol Microbiol Infect Dis 1993;
 370 16:299 -305.
- 371 20. Surolia A, Pain D, Khan MI. Protein A: nature's universal anti-antibody. TIBS
 372 1982; 74-6.

373	21. Costa ECV, Sobreira M, Leal NC, Almeida AMP. Rodents and other small
374	mammal reservoirs in plague foci in northeastern Brazil. Journal of Infection in
375	Developing Countries 2017; 11:426-30.

- 22. Sousa LLF, Alencar CH, Almeida AMP, Cavalcanti LPG. Seroprevalence and
 spatial distribution dynamics of *Yersinia pestis* antibodies in dogs and cats from
 plague foci in the State of Ceará, Northeastern Brazil. Revista da Sociedade
 Brasileira de Medicina Tropical 2017; 50:769-76.
- 380 23. Tavares DHC, Bezerra MF, Magalhães F et al. A new recombinant F1 antigen as
 a cost and time-effective tool for plague diagnosis. J Microbiol Meth 2020;
 172:105903.
- 24. Bevins SN, Baroch JA, Nolte DL, Zhang M, Hongxuan HE. *Yersinia pestis*:
 examining wildlife plague surveillance in China and the USA. Integrative
 Zoology 2012; 7:99-109.
- 25. Almeida AMP, Sobreira M, Leal NC, Tavares C. Does the Plague Still Threaten
 Us? Rev Soc Bras Med Trop 2020; 53:e20190136.
- Andrianaivoarimanana V, Iharisoa AL, Rahalison L, et al. Short- and long-term
 humoral immune response against *Yersinia pestis* in plague patients, Madagascar.
- BMC Infectious Diseases 2020; 20:822.
- 391 27. Butler T and Hudson BW. The serological response to *Yersinia pestis* infection.
 392 Bull World Health Organ 1977; 55:39-42.
- 393
- 555
- 394
- 395
- 396
- 397

FIGURES LEGENDS

Figure 1. Standardization of Protein A-ELISA, F1 antigen purified from the A1122 Y. pestis strain in culture (A). Three concentrations of F1 antigen (250 ng, 375 ng and 500 ng) were tested. The assay was optimized at the concentration of 250 ng of F1 antigen per well (B). Graph with the optical densities from titrated sera in different species (C).

Figure 2. Linearity and precision of Protein A-ELISA. Good correlation (Pearson=0.97) was observed between the Protein A and IgG ELISA tests using control rabbit sera (n = 81). Dashed lines represent the 95% confidence interval and the white datapoint, an outlier samples excluded from correlation analysis (A). From the total 553 samples tested for Protein A-ELISA, 88% had a coefficient of variation (CV) of the triplicates lower than 10% and 93% of the samples had a CV lower than 15%. The line shows the cumulative percentage of samples within the respective CV level and the bars show the absolute amounts of samples in each interval of CV value (B).

Figure 3. Validation of the diagnosis of plague by Protein A-ELISA and IgG-ELISA 423

424 in HA-tested sera. Comparison between ODs from positive and negative sera for Protein

A-ELISA. The cut-off in Protein A-ELISA was 0.130 for all species (A). For IgG-ELISA, 425

the cut-offs were 0.258 (rabbits), 0.320 (humans) and 0.573 (dogs). All sera were 426

previously tested for hemagglutination (B). Area under the curve (AUC) for protein A 427

(C) and IgG (D) conjugates. AUC values close to 1.0 indicate good test performance. 428

429

Supplementary Figure 1. Standardization of IgG-ELISA. Four distinct titers were 430 tested for each anti-IgG conjugates in triplicate for one positive and one negative serum 431 432 from each species. Antigen concentration and sample titer were the same from the 433 previously established in the Protein A-ELISA assay.

434

435 Supplementary Figure 2. Coefficient of variation in Protein A-ELISA according to the average OD. The majority of the samples tested for Protein A-ELISA (n=553) had 436 437 triplicates with low CVs. Higher variation was found in negative samples, with the ODs

close to the lower detection limit, where small numeric variations implies in high CVs. 438

439

440 Supplementary Figure 3. ROC curves for Protein A-ELISA. Stratified ROC curves and area under the curve (AUC) for protein A-ELISA according to each evaluated 441 species. 442







Conjugate titer (IgG)



Supplementary Figure



Supplementary Figure



Supplementary Figure